Education
About Us
Working with TipRanks
Follow Us
Biovica International AB Class B (DE:9II)
FRANKFURT:9II
9II Stock Chart & Stats
€0.02
-€0.05(-28.13%)
At close: 4:00 PM EST
€0.02
-€0.05(-28.13%)
Day’s Range― - ―
52-Week Range€0.01 - €0.15
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.44M
Enterprise Value-€40.60M
Total Cash (Recent Filing)€100.66M
Total Debt (Recent Filing)€3.04M
Price to Earnings (P/E)―
Beta2.88
Next Earnings
Mar 18, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding277,487,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.50
Price to Sales (P/S)7.52
P/FCF Ratio-0.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€1.25M
Bulls Say, Bears Say
Bulls Say
Proprietary Diagnostic Platform & Oncology FocusBiovica's proprietary DiviTum assay and focused oncology positioning create a durable product moat: specialized biomarker tests are hard to replicate quickly, support clinical adoption in cancer care and provide a platform for recurring clinical and pharma trial revenue streams if validated and adopted.
Rapid Reported Revenue GrowthStrong TTM revenue growth indicates early commercial traction and expanding end-market adoption. If sustained, scaling revenue can absorb fixed costs, improve unit economics, and reduce the reliance on financing, turning growing top-line momentum into durable operational leverage.
Low Leverage And Balance-sheet FlexibilityVery low debt reduces near-term solvency risk and gives management flexibility to invest in commercialization or R&D. This lowers refinancing pressure and extends runway compared with highly leveraged peers, an enduring advantage while the business scales or seeks partnerships.
Bears Say
Heavy Operating Cash BurnSustained, large negative operating and free cash flow sharply increases dependency on external funding. Over months this raises dilution risk and constrains strategic options; without material revenue scale or cost reductions, cash burn threatens viability of current growth plans.
Negative Gross Profit In TTMA negative TTM gross profit implies product-level economics or recent accounting/cost issues that overwhelm revenue. If this persists, the core diagnostic business cannot be profitable at scale, undermining long-term viability unless pricing, cost structure, or revenue recognition anomalies are resolved.
Large Cumulative Losses And Negative ReturnsDeep losses and highly negative ROE reflect persistent unprofitability and erosion of equity value. Over time this forces reliance on dilutive financings or strategic exits, reducing shareholder value and signalling that operations have yet to achieve sustainable profitability.
Biovica International AB Class B News
9II FAQ
What was Biovica International AB Class B’s price range in the past 12 months?
Biovica International AB Class B lowest stock price was €0.01 and its highest was €0.15 in the past 12 months.
What is Biovica International AB Class B’s market cap?
Biovica International AB Class B’s market cap is €7.44M.
When is Biovica International AB Class B’s upcoming earnings report date?
Biovica International AB Class B’s upcoming earnings report date is Mar 18, 2026 which is in 10 days.
How were Biovica International AB Class B’s earnings last quarter?
Biovica International AB Class B released its earnings results on Dec 18, 2025. The company reported -€0.005 earnings per share for the quarter, beating the consensus estimate of -€0.008 by €0.002.
Is Biovica International AB Class B overvalued?
According to Wall Street analysts Biovica International AB Class B’s price is currently Overvalued.
Does Biovica International AB Class B pay dividends?
Biovica International AB Class B does not currently pay dividends.
What is Biovica International AB Class B’s EPS estimate?
Biovica International AB Class B’s EPS estimate is >-0.01.
How many shares outstanding does Biovica International AB Class B have?
Biovica International AB Class B has 277,487,200 shares outstanding.
What happened to Biovica International AB Class B’s price movement after its last earnings report?
Biovica International AB Class B reported an EPS of -€0.005 in its last earnings report, beating expectations of -€0.008. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biovica International AB Class B?
Currently, no hedge funds are holding shares in DE:9II
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biovica International AB Class B
Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Nanologica AB
―
Lipigon Pharmaceuticals AB
―
NextCell Pharma AB
―